ATE366808T1 - Chimäre oligonukleotide und deren verwendungen in der identifizierung von antisense-bindungsstellen - Google Patents
Chimäre oligonukleotide und deren verwendungen in der identifizierung von antisense-bindungsstellenInfo
- Publication number
- ATE366808T1 ATE366808T1 AT96930282T AT96930282T ATE366808T1 AT E366808 T1 ATE366808 T1 AT E366808T1 AT 96930282 T AT96930282 T AT 96930282T AT 96930282 T AT96930282 T AT 96930282T AT E366808 T1 ATE366808 T1 AT E366808T1
- Authority
- AT
- Austria
- Prior art keywords
- mrna
- duplex
- sequence
- cutting
- nucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 7
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 108060002716 Exonuclease Proteins 0.000 abstract 1
- 102000013165 exonuclease Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9518864.5A GB9518864D0 (en) | 1995-09-14 | 1995-09-14 | Oligonucleotides and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366808T1 true ATE366808T1 (de) | 2007-08-15 |
Family
ID=10780749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96930282T ATE366808T1 (de) | 1995-09-14 | 1996-09-13 | Chimäre oligonukleotide und deren verwendungen in der identifizierung von antisense-bindungsstellen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6355418B1 (de) |
| EP (1) | EP0857208B1 (de) |
| JP (1) | JP3662027B2 (de) |
| AT (1) | ATE366808T1 (de) |
| AU (1) | AU6939496A (de) |
| DE (1) | DE69637158D1 (de) |
| GB (1) | GB9518864D0 (de) |
| WO (1) | WO1997010332A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9620749D0 (en) * | 1996-10-04 | 1996-11-20 | Brax Genomics Ltd | Identifying antisense oligonucleotides |
| AU744369B2 (en) * | 1997-05-05 | 2002-02-21 | Third Wave Technologies, Inc. | Target-dependent reactions using structure-bridging oligonucleotides |
| WO1999027086A1 (en) * | 1997-11-25 | 1999-06-03 | Brax Group Limited | Chimeric antisense oligonucleotides against tnf-alpha and their uses |
| US20030144496A1 (en) * | 1997-12-04 | 2003-07-31 | Crooke Stanley T. | Human RNase H and compositions and uses thereof |
| PT1042001E (pt) * | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
| GB2335034B (en) * | 1998-03-03 | 2003-08-20 | Brax Genomics Ltd | Screening for functional antisense agents |
| DE19819735A1 (de) * | 1998-05-02 | 1999-11-04 | Novartis Ag | Vorrichtung und Verfahren zur Herstellung einer Anordnung von Kettenmolekülen auf einem Trägermaterial |
| US6080580A (en) * | 1998-10-05 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression |
| US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| WO2000042178A2 (en) * | 1999-01-13 | 2000-07-20 | Dupont Pharmaceuticals Company | Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function |
| US6677445B1 (en) * | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| CA2392959A1 (en) * | 1999-12-02 | 2001-06-07 | Signalgene Inc. | Preparation of sequence libraries from non-denatured rna and kits therefor |
| CN105388293A (zh) * | 2008-12-31 | 2016-03-09 | 雅培医护站股份有限公司 | 用于使用核苷酸缀合物的免疫测定的方法和设备 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3019994B2 (ja) * | 1987-11-30 | 2000-03-15 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法 |
| US5525468A (en) * | 1992-05-14 | 1996-06-11 | Ribozyme Pharmaceuticals, Inc. | Assay for Ribozyme target site |
| DE4424762C1 (de) * | 1994-07-04 | 1995-07-27 | Max Planck Gesellschaft | Ribozym-Bibliothek, ihre Herstellung und ihre Verwendung |
-
1995
- 1995-09-14 GB GBGB9518864.5A patent/GB9518864D0/en active Pending
-
1996
- 1996-09-13 US US09/043,149 patent/US6355418B1/en not_active Expired - Fee Related
- 1996-09-13 EP EP96930282A patent/EP0857208B1/de not_active Expired - Lifetime
- 1996-09-13 AU AU69394/96A patent/AU6939496A/en not_active Abandoned
- 1996-09-13 JP JP51177297A patent/JP3662027B2/ja not_active Expired - Fee Related
- 1996-09-13 WO PCT/GB1996/002275 patent/WO1997010332A2/en not_active Ceased
- 1996-09-13 AT AT96930282T patent/ATE366808T1/de not_active IP Right Cessation
- 1996-09-13 DE DE69637158T patent/DE69637158D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69637158D1 (de) | 2007-08-23 |
| EP0857208B1 (de) | 2007-07-11 |
| JPH11514220A (ja) | 1999-12-07 |
| WO1997010332A2 (en) | 1997-03-20 |
| EP0857208A2 (de) | 1998-08-12 |
| WO1997010332A3 (en) | 1997-05-15 |
| JP3662027B2 (ja) | 2005-06-22 |
| US6355418B1 (en) | 2002-03-12 |
| GB9518864D0 (en) | 1995-11-15 |
| AU6939496A (en) | 1997-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69637158D1 (de) | Chimäre oligonukleotide und deren verwendungen in der identifizierung von antisense-bindungsstellen | |
| Peng Ho et al. | Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries | |
| ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
| DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| EP0664836A1 (de) | Verfahren für die sequenzierung von synthetischen oligonukleotiden, die nicht phosphodiester internukleotidische bindungen enthalten. | |
| DE3855864D1 (de) | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene | |
| NZ334987A (en) | A method for identifying antisense oligonucleotides that bind a target mRNA | |
| BR9812650A (pt) | ácidos nucléicos hibridizando marcação múltipla, preparação dos mesmos, composições, formulação, kits e aplicações | |
| DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
| ATE216705T1 (de) | Antisense-oligonukleotidmodulation der raf- genexpression | |
| PT92640A (pt) | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use | |
| DE69833438D1 (de) | Hiv-spezifische oligonukleotide und verfahren zu deren verwendung | |
| DK2080813T3 (da) | Nukleinsyreligander, som binder til og inhiberer DNA-polymeraser | |
| DE10080169D2 (de) | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben | |
| ATE478157T1 (de) | Nukleinsäure-ligand-inhibitoren gegen dna polymerasen | |
| ATE273718T1 (de) | Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression | |
| ATE403747T1 (de) | Verfahren zur amplifikation von signal- flankierenden sequenzen aus unbekannten, genomischen daten | |
| ATE258596T1 (de) | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen | |
| EP1002126A4 (de) | Verbessertes verfahren zur isolierung und wiedergewinnung von ziel-dna oder -rna molekülen mit einer gewünschten nukleotidsequenz | |
| TR200000384T2 (tr) | Oligonükleotitlerin çözelti fazlı sentezi. | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| DE69501081D1 (de) | Oligonukleotide mit anti-cytomegalovirus wirkung | |
| ATE318617T1 (de) | Synthetische oligonukleotide als erythroid differenzierungserreger | |
| ATE280244T1 (de) | Verfahren zum nachweis von lebensfähigen cryptosporidium parvum oozysten | |
| Okuizumi et al. | Application of the RLGS method to large-size genomes using a restriction trapper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |